FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年12月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔 ...

Core Insights - Huawei has officially launched the AI Data Platform for the healthcare sector, aimed at addressing the cost, quality, and accessibility challenges in the medical field through advanced technologies [1][4] - The AI Data Platform supports the "Rui Bin 2" medical intelligence system, developed in collaboration with West China Hospital, providing comprehensive diagnostic services for patients and research support for doctors [4] - The Chinese government is actively promoting the digital transformation of healthcare, with policies aimed at integrating AI into various medical applications, projecting significant growth in the AI healthcare market [5] Industry Developments - The AI healthcare market in China is expected to reach 115.7 billion yuan by 2025, with a compound annual growth rate (CAGR) of 10.5% from 2022 to 2028, potentially growing to 159.8 billion yuan by 2028 [5] - Several listed companies are forming AI healthcare industry clusters, integrating AI technologies into various medical applications, such as blood purification and imaging diagnostics [6] - The application of AI in healthcare is seen as a key turning point, driven by technological advancements and policy support, creating a new theme for industry innovation [7] Company Highlights - Eagle Eye Technology (02251) is recognized for its AI retinal imaging diagnostic solutions, which can automatically capture and analyze retinal images, identifying various diseases [8] - Yidu Tech (02158) has made significant progress in AI healthcare innovation, establishing a closed-loop system of data, algorithms, and scenarios to accelerate business deployment [8] - Ping An Good Doctor (01833) reported a 19.5% year-on-year revenue increase, attributed to advancements in AI healthcare, prompting analysts to raise its target price [9] - iFlytek Medical Technology (02506) leads in the medical AI field with its comprehensive medical model, showcasing strong performance in various core capabilities [9]

Core Viewpoint - The company demonstrates strong confidence in its business development through share buybacks and reports solid financial performance, indicating sustainable growth potential in the healthcare technology sector [1]. Financial Performance - On December 8, the company announced a share buyback of 225,000 shares at HKD 5.24 per share, totaling approximately HKD 1.18 million [1]. - The cumulative buyback over four trading days reached about 1.08 million shares, with a total expenditure exceeding HKD 5.5 million [1]. - For the fiscal year 2026 mid-term results, total revenue was RMB 358 million, reflecting an 8.7% year-on-year growth [1]. - Adjusted EBITDA for existing business was approximately RMB 54 million, doubling compared to the same period last year, nearing breakeven on the accounting level [1]. Business Development and Industry Recognition - The company, in collaboration with the Weifang Health Commission in Shandong Province, successfully applied for the "Health Portrait" and "Weifang City Universal Health Digital Portrait" projects [1]. - The company received two significant provincial awards: the "First Prize for Beneficial Service Practice" in the 2025 Shandong Province "Internet + Healthcare" Innovation Application Case and the "Service Innovation First Prize" in the inaugural "Qilu Digital Medical Health" Innovation Competition [1]. - These achievements highlight the company's role as a benchmark case for AI medical technology empowering regional health management [1].

Core Viewpoint - The company demonstrates strong confidence in its business development through share buybacks and reports solid financial performance, indicating sustainable growth potential in the healthcare technology sector [1]. Group 1: Share Buyback - On December 8, the company repurchased 225,000 shares at a price of HKD 5.24 per share, totaling approximately HKD 1.18 million [1]. - The company has conducted share buybacks for four consecutive trading days, accumulating around 1.08 million shares with a total expenditure exceeding HKD 5.5 million [1]. Group 2: Financial Performance - For the fiscal year 2026 mid-term, the company reported total revenue of RMB 358 million, reflecting a year-on-year growth of 8.7% [1]. - The adjusted EBITDA for existing operations reached approximately RMB 54 million, doubling compared to the same period last year, nearing breakeven on the accounting level [1]. - This financial milestone was achieved about one year ahead of the management's original expectations, highlighting the sustainability and growth potential of the business model [1]. Group 3: Industry Recognition - The company, in collaboration with the Weifang Health Commission in Shandong Province, successfully won two provincial awards for its "Health Portrait" and "Weifang City Universal Health Digital Portrait" projects [1]. - The awards include the "First Prize for Beneficial Service Practice" in the 2025 Shandong Province "Internet + Healthcare" Innovation Application Case and the "Service Innovation First Prize" in the inaugural "Qilu Digital Healthcare" Innovation Competition, establishing a benchmark case for AI medical technology in regional health management [1].

格隆汇12月8日丨医渡科技(02158.HK)公告，12月8日耗资117.8万港元回购22.5万股，回购价格每股5.21- 5.25港元。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2025年12月8日，该公司斥资117.82万港元回购22.5万股 股份，每股回购价5.21-5.25港元。 ...

医渡科技(02158)发布公告，于2025年12月8日，该公司斥资117.82万港元回购22.5万股股份，每股回购 价5.21-5.25港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年12月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

Core Insights - Multiple companies, including Tencent Holdings and China Petroleum & Chemical Corporation, conducted share buybacks on December 5, 2025, with Tencent leading in both volume and monetary value [1][2] Company Summaries - **Tencent Holdings (00700)**: Repurchased 1.046 million shares for a total of 636 million, with a year-to-date total of 85.148 million shares, representing 0.927% of total share capital [2] - **China National Offshore Oil Corporation (01919)**: Bought back 3 million shares for 41.6745 million, with a cumulative total of 6.9543 million shares, accounting for 2.415% of total share capital [2] - **Kuaishou-W (01024)**: Acquired 438,000 shares for 29.9859 million, with a year-to-date total of 682,460 shares, representing 0.159% of total share capital [2] - **Fenbi (02469)**: Conducted a buyback of 6.657 million shares for 21.0954 million, with a cumulative total of 26.657 million shares, accounting for 1.193% of total share capital [2] - **Jinxin Fertility (01951)**: Repurchased 7.722 million shares for 19.7977 million, with a total of 7.722 million shares year-to-date, representing 0.280% of total share capital [2] - **Yum China (09987)**: Engaged in two buybacks, totaling 57,000 shares for 19.1905 million, with a cumulative total of 16.2024 million shares, accounting for 4.350% of total share capital [2] - **China Feihe (06186)**: Bought back 3 million shares for 12.3 million, with a cumulative total of 208 million shares, representing 2.295% of total share capital [2] - **Haier Smart Home (06690)**: Acquired 450,000 shares for 12.1991 million, with a total of 330,000 shares year-to-date, representing 0.116% of total share capital [2] - **Vitasoy International (00345)**: Repurchased 1.302 million shares for 8.6504 million, with a cumulative total of 1.928 million shares, accounting for 1.837% of total share capital [2] - **Coolpad Group (02369)**: Conducted a buyback of 4.144 million shares for 5.5725 million, with a total of 15.048 million shares year-to-date, representing 3.925% of total share capital [2]

Group 1 - The core viewpoint of the article highlights that Yidu Tech (02158) has been actively repurchasing shares for three consecutive days, signaling positive market sentiment [1] - On December 5, the company repurchased 280,000 shares at a price of HKD 5.18 per share, totaling HKD 1.4 million, bringing the total repurchased shares to approximately 853,000 and the cumulative repurchase amount to over HKD 4.3 million [1] - Yidu Tech reported a healthy revenue growth for the fiscal year 2026, with total revenue reaching RMB 358 million, representing a year-on-year increase of 8.7% [1] Group 2 - The company achieved a significant milestone in profitability, with adjusted EBITDA from existing operations reaching approximately RMB 54 million, doubling compared to the same period last year, and nearing breakeven on the financial statements [1] - This key financial milestone was achieved approximately one year ahead of the management's previous expectations [1] - Yidu Tech has officially launched a digital technology research and development platform in collaboration with Tsinghua Changgung Hospital, marking a new phase in their partnership in the field of medical artificial intelligence [1]